Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
about
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesNonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansSynthetic DNA vaccine strategies against persistent viral infectionsImmunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectorsVaxvec: The first web-based recombinant vaccine vector database and its data analysisInsertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigensDendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.HIV vaccines: lessons learned and the way forward.Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysInterleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsThe immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military PopulationsSafety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.Pre-existing immunity against vaccine vectors--friend or foe?Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization.Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
P2860
Q21135240-1D2ADD79-EE45-4B41-9CBB-5FECCF5B80C6Q26861148-9469CFCC-00B2-40E1-90F7-A8EB03A29201Q26995078-D1E30006-14EB-49A3-8309-835E2733B9B9Q27016078-4843DCD6-CD13-4A0E-9DCA-08A467C51FB4Q27320923-4C8CAB07-05FB-477E-AA2C-5701A8C6B831Q27321063-410BD1E7-D61C-4BFD-AFEA-16D19B609AFAQ28742751-F981C22C-C155-437B-BE39-9461D252EC32Q30996881-F8DF2219-08DC-429A-8F59-F28F91A303C1Q33627613-27A94F02-63EF-4B97-AC3A-80AED187DA41Q33916776-A220B35A-68C4-4FF1-B957-167ED9D3CEE0Q34342558-2870E2E6-67F5-4F04-8365-640389974971Q34673436-B4F38DFF-EF8F-4DA7-B7B5-8FDD08962EA6Q34796206-152F596B-307C-4B71-8087-270F889A8882Q35488175-9F0045A2-2105-4EFE-88B9-0388803B0ADBQ35571248-50FABADA-3676-4FD2-A3D2-8125D299663AQ35634159-BCE223F4-DDC5-40DD-BB2A-7A45C9D4AF15Q35867988-C70733E5-82B5-433B-BC23-B70E6D579ADFQ36238314-6870F130-8AAD-4858-B8C2-450AE6462395Q36668517-B650918F-1730-4DAB-BB07-2C6DE36094BCQ36849770-719B6DEC-11A5-4A22-856F-F08C43E44E83Q36911682-82CD66F2-A381-409C-B245-FA4AE179B3C8Q37785949-A146D692-013F-433D-82B1-5A2BCA772178Q37791160-351141FB-63A9-4FA2-A39F-D297ECE17C93Q38061876-63623A94-AF35-46F4-9C33-DBF10749E6D8Q41649964-1B21D44D-C487-4695-A704-552403709A33Q44569389-320DA905-A91F-4A11-8061-FC69D904B694Q47375908-9708DF4C-447C-4650-80CD-64D227532307
P2860
Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@ast
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@en
type
label
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@ast
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@en
prefLabel
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@ast
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@en
P356
P1433
P1476
Attenuated poxvirus vectors MV ...... e candidates against HIV/AIDS.
@en
P2093
Mariano Esteban
P304
P356
10.4161/HV.9693
P577
2009-12-03T00:00:00Z